Home Newsfeeds RBC Capital Maintains Outperform on Chemours, Raises Price Target to $48

RBC Capital Maintains Outperform on Chemours, Raises Price Target to $48

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $44 to $48.

byBenzinga Newsdesk

August 1, 2022

1 minute read

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $44 to $48.

This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

By Avi Kapoor

May 24, 8:46 AM

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

BILI

Viridian Therapeutics To Provide Key Updates On The Company’s Anti-Insulin-Like Growth Factor 1 Receptor Programs In Thyroid Eye Disease And Its Programs Targeting FcRn; VRDN-001 U.S. Annual Revenue ~$2B

By Benzinga Newsdesk

January 8, 9:17 AM

Thyroid Eye Disease Portfolio: VRDN-001 and VRDN-003Intravenous VRDN-001Viridian's lead product candidate, VRDN-001, is a monoclonal antibody that acts as a full antagonist of IGF-1R, a clinically and commercially

VRDN

News

Indie Semiconductor And SiLC Technologies Form Strategic Technology Partnership To Deliver World-Class FMCW LiDAR Solution

By Happy Mohamed

August 3, 9:48 AM

FMCW LiDAR platform integrates indie's SuryaTM SoC and SiLC's EyeonicTM Vision Sensor, enabling the industry's most compact and highest performance coherent vision system Collaboration delivers

INDI

News

Beam Therapeutics Reports Progress Across Base Editing Portfolio And Outlines Key Anticipated Milestones

By Benzinga Newsdesk

January 9, 7:42 AM

BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with

BEAM

RBC Capital Maintains Outperform on Chemours, Raises Price Target to $48

Related Posts

This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Viridian Therapeutics To Provide Key Updates On The Company’s Anti-Insulin-Like Growth Factor 1 Receptor Programs In Thyroid Eye Disease And Its Programs Targeting FcRn; VRDN-001 U.S. Annual Revenue ~$2B

Indie Semiconductor And SiLC Technologies Form Strategic Technology Partnership To Deliver World-Class FMCW LiDAR Solution

Beam Therapeutics Reports Progress Across Base Editing Portfolio And Outlines Key Anticipated Milestones